MedTrace Logo

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

NCT02312882 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-11-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Conditions

Interventions

DRUG

Tofacitinib

Tofacitinib 5 mg tablet taken by mouth twice a day.

Sponsors & Collaborators

Principal Investigators

  • Anthony E Oro, M.D., Ph.D. · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312882 on ClinicalTrials.gov